In patients with heart failure, plasma levels of A-type and B-type natriuretic peptides appear to be more sensitive than conventional measures of cardiac function in monitoring the effects of treatment with angiotensin-converting enzyme (ACE) inhibitors, according to a study in the June 15th issue of The American Journal of Medicine.
While circulating levels of these peptides are known to predict the severity of heart failure, it was unclear how these levels respond to changes in cardiac function as a result of ACE inhibitor therapy.
Dr. Michihiro Yoshimura, from Kumamoto University School of Medicine in Japan, and colleagues measured levels of A-type and B-type natriuretic peptides in 24 patients with chronic heart failure who were treated with enalapril at a dose of 5 mg/day for 3 months.
After 3 months, half of the patients continued enalapril at the same dose for an additional 3 months, while half received a 15-mg/day dose. Echocardiographic parameters and cardiothoracic ratios were also determined for comparison.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!